New Zealand markets open in 6 hours 28 minutes

10x Genomics, Inc. (TXG)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
19.55-0.47 (-2.35%)
As of 10:32AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.41B
Enterprise value 2.12B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.77
Price/book (mrq)3.33
Enterprise value/revenue 3.36
Enterprise value/EBITDA -40.69

Trading information

Stock price history

Beta (5Y monthly) 1.85
52-week change 3-48.78%
S&P500 52-week change 332.65%
52-week high 357.90
52-week low 315.28
50-day moving average 321.52
200-day moving average 330.93

Share statistics

Avg vol (3-month) 31.8M
Avg vol (10-day) 31.35M
Shares outstanding 5106.44M
Implied shares outstanding 6120.49M
Float 8104.4M
% held by insiders 12.18%
% held by institutions 196.91%
Shares short (13 Sept 2024) 47.81M
Short ratio (13 Sept 2024) 45.55
Short % of float (13 Sept 2024) 48.50%
Short % of shares outstanding (13 Sept 2024) 46.48%
Shares short (prior month 15 Aug 2024) 410.42M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 Jun 2024

Profitability

Profit margin -37.96%
Operating margin (ttm)-27.26%

Management effectiveness

Return on assets (ttm)-11.95%
Return on equity (ttm)-31.60%

Income statement

Revenue (ttm)631.73M
Revenue per share (ttm)5.32
Quarterly revenue growth (yoy)4.30%
Gross profit (ttm)N/A
EBITDA -146.28M
Net income avi to common (ttm)-239.78M
Diluted EPS (ttm)-2.03
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)380.09M
Total cash per share (mrq)3.15
Total debt (mrq)89.48M
Total debt/equity (mrq)12.36%
Current ratio (mrq)5.22
Book value per share (mrq)6.01

Cash flow statement

Operating cash flow (ttm)-7.78M
Levered free cash flow (ttm)62.79M